TREATMENT OF PERSISTENT COVID WITH EXTRACELLULAR VESICLE COMPOSITION

PY2498885APending Publication Date: 2026-04-29DIRECT BIOLOGICS LLC

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: PY2498885P0
Authority / Receiving Office: PY · PY
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-10-25
Filing Date: 2024-11-07
Publication Date: 2026-04-29

Application Information

Patent Timeline

25 Oct 2024

Priority

07 Nov 2024

Application

PY2498885P0

29 Apr 2026

Publication

PY2498885A

IPC: A61K35/28; A61P31/14; A61P43/00

CPC: A61P31/14; A61K38/16; C12N15/113; A61K31/713; C12N2310/141

Inventors: Emil J. Schmidt; Kenneth Allen Pettine

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

Long COVID, or post-acute sequelae of COVID-19 (PASC), is a prolonged and debilitating syndrome that follows acute SARS-CoV-2 infection in >10% of cases. Extracellular vesicles derived from human bone marrow mesenchymal stem cells (hBM-MSC EVs) may represent a novel therapeutic option.

Need to check novelty before this filing date? Find Prior Art